The Europe home infusion therapy market is expected to reach USD 14,618 million by 2030, with a CAGR of 8.9%.
An alternative to taking medication by mouth is infusion therapy, which is how the term is defined. The infusion process involves monitoring the administration of medication with the assistance of a sterile catheter inserted into a vein.
Home infusion therapy refers to giving an individual medication or biologicals through an intravenous or subcutaneous route while they live in their residence. The medication (such as antivirals or immune globulin, for example), the necessary piece of medical equipment (such as a pump), and the necessary medical supplies are required to carry out home infusion (for example, tubing and catheters). In a similar vein, nursing services are required to educate and train both the patient and the caregivers administering the infusion medications in the patient's home. Home infusion treatment frequently requires a significant contribution from visiting nurses. Typically, nurses will instruct the patient or the caregiver on how to self-administer the medication, educate the patient about the potential adverse effects of the treatment and the aims of therapy, and visit the patient occasionally to evaluate the infusion site and change the dressing. In most cases, the procedure of home infusion needs coordination among several different parties. These parties can include patients, physicians, hospital discharge planners, health plans, home infusion pharmacies, and, if necessary, home health organisations.
Get more information on this report Download Sample Report
The growing elderly population & increasing demand for long-term care
One of the significant drivers of the home infusion therapy market is the growing elderly population, prone to various severe disorders. The growing geriatric population and the rising prevalence of cancer, Crohn's disease, multiple sclerosis, nutritional and immune deficiencies, infections, dehydration, and nausea and vomiting are driving the trend. Because the virus is transmitted through physical contact, the COVID-19 outbreak increased the importance and demand for medical devices, particularly in a home-based setting.
The market for home infusion therapy in Europe is expected to grow significantly due to increased chronic disorders among individuals and growing government initiatives promoting the benefits of home infusion therapy. Furthermore, rising patient demand for long-term therapies is expected to drive market growth.
Two major factors are driving the market growth: the increasing geriatric population and an increase in disease burden are two significant factors driving the market growth. Furthermore, increased awareness has resulted in a greater preference for home infusion therapy among patients requiring long-term care, particularly the senior population.
Another driver of market growth is the well-established healthcare industry, easy access to healthcare needs, faster adoption of advanced technologies, and high disposable income of consumers. The availability of high-quality home infusion products for patients is also propelling the market growth.
The presence of a complex reimbursement framework as well as reimbursement cuts
One of the major factors driving the market growth is Medicare reimbursement for home healthcare providers and patients. Recent reimbursement cuts and rebasing of home health funding, on the other hand, are expected to impede market growth during the forecast period. Medicare proposed cutting home health funding by 3.5 per cent per year from 2014 to 2017 in its draught of the Home Health Prospective Payment System (HPPS) rule for 2014. This is expected to significantly impact home health funding and limit patients' and senior citizens' ability to access clinically advanced and cost-effective home-based care. Rebasing has resulted in lower average margins, which have fallen from 8.6 per cent in 2014 to 5.0 per cent in 2017. Furthermore, the elimination of 170 ICD-9 codes from home healthcare reimbursement policies is expected to limit market growth during the forecast period.
The Europe home infusion therapy market is classified into two types: products and services.
Further, it is divided into four product categories: infusion pumps, intravenous sets, iv cannulas, and needleless connectors. Infusion pumps accounted for the largest market share due to their widespread use in delivering fluids, including drugs and nutrition. Many infusion pumps are available, including enteral pumps, syringe pumps, multi-channel pumps, and peristaltic pumps.
On the other hand, needless connectors are expected to become more popular. The benefits of these devices, such as reduced bacterial contamination and increased protection against needlestick injuries, have aided the market's growth. As home healthcare becomes more common, the demand for syringes and ambulatory pumps rises.
Smart pumps with barcode technology help validate a patient's identity, preventing incorrect medicine from being administered to the patient. These pumps also notify healthcare workers if they choose an incorrect drug dosage. The introduction of technologically advanced infusion pumps, such as the CADD-Solis ambulatory infusion pump, is expected to drive infusion pump market growth during the forecast period.
Anti-infective, endocrinology, hydration therapy, chemotherapy, enteral nutrition, parenteral nutrition, and speciality pharmaceuticals are the application segments of the home infusion therapy market.
The parenteral nutrition market is expected to grow significantly during the forecast period due to increasing government initiatives to raise awareness about parenteral nutrition.
Countrywise Growth Insights Request Sample Pages
The Europe home infusion therapy market is divided into the UK, Germany, France, Italy, and the Rest of Europe, based on country. According to the World Health Organization, Europe sees 3.7 million new cancer cases and 1.9 million cancer deaths each year, making it the second most common disease after heart disease. This has resulted in increased demand for physician-directed home infusions and related services, which is both cost-effective and less taxing on healthcare facilities.